Tuesday, June 23, 2015

EPIRUS Biopharmaceuticals: Innovating Products for Inflammatory and Immunology Diseases

With the advancement of technology and medicine, pharmaceutical companies are able to create products that are able to counter life-threatening diseases. Sadly though, the majority of these products is sold with skyrocketing prices. With the cost of medication going up, not that many people are able to purchase these medications despite their urgency of their needs. Thanks to biopharmaceutical companies like EPIRUS Pharmaceuticals, they are able to change the way the majority accesses to these therapeutics.

EPIRUS Pharmaceuticals continues to offer the market their biosimilar products that are patented after three branded products. These medications are used to treat serious diseases in relation to immunology and inflammation. They continue to develop, manufacture and commercialize their products in targeted geographies around the world. They are currently marketing their BOW015 (infliximab), BOW050 (adalimumab) and BOW070 (tocilizumab) that are patterned after Remicade, Humira and Actemra, respectively. The last three products have a very strong performance in the global markets and the demand for these medications have totaled to more than $20 billion in global sales during the 2013 fiscal year.

BOW015 is a biosimilar product that is intended as a treatment for rheumatoid arthritis. This product is being marketed under the name Infimab and is also used as a treatment for psoriatic arthritis, psoriasis, ankylosing spondylitis and Crohn’s Disease.  BOW050 contains adalimumab as its active ingredient. This product is also used as a treatment for inflammatory diseases, including pediatric arthritis and inflammatory bowel disease. The BOW070, marketed as Tocilizumab is also intended for various forms of inflammatory diseases and is currently in its comparability phase of development.

Headquartered in Boston, Massachusetts, EPIRUS Biopharmaceuticals continues to employ the assistance  of local distributors, licensing, and direct sales to commercialize their offerings. They also partner with local companies to hasten the distribution of their products in the market.

No comments:

Post a Comment